Patent Grant
8980926
Malaria is a vector-borne infectious disease caused by protozoan parasites and is widespread in tropical and subtropical regions, including parts of the Americas, Asia and Africa. Of the five Plasmodium parasite species that can infect humans (P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi), the most serious forms of the disease are caused by P. falciparum and P. vivax. Of the approximately 515 million people infected yearly, between one and three million people, the majority of whom are young children in Sub-Saharan Africa, die from the disease. The current armament of approved anti-malarial drugs, such as chloroquine, atovaquone, pyrimethamine, and sulfadoxine, is limited to only a few targets within the human malaria parasite, and growing widespread resistance to current drugs is prompting the development of new antimalarial agents that have new biological targets.
It has now been found that a novel class of compounds based on a 2-aminoindole scaffold (referred to herein as “2-aminoindoles”) has efficacy in the treatment of malaria. Representative compounds disclosed herein exhibit potent anti-malaria activity in vitro and in vivo and likely act via a mechanism that has not been utilized in malaria drug development. Some representatives of the class have been shown to cure malaria in a rodent model.
Accordingly, in one embodiment, the present invention relates to methods of treating a subject with malaria, comprising administering to the subject in need thereof an effective amount of a 2-aminoindole compound of the invention.
In another embodiment, the invention relates to 2-aminoindole compounds described herein.
In a further embodiment, the invention relates to compositions (e.g., pharmaceutical compositions) comprising a 2-aminoindole compound described herein.
In an additional embodiment, the invention relates to methods of preparing 2-aminoindole compounds described herein.
In a first embodiment, the present invention is a method of treating a subject with malaria, comprising administering to the subject in need thereof an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof,
wherein
In a second embodiment, the present invention is a compound of Formula IIa:
or a pharmaceutically acceptable salt thereof,
wherein
In a third embodiment, the present invention is a pharmaceutical composition comprising the compound of Formula IIa, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
In a fourth embodiment, the present invention is a compound of Formula VI:
or a pharmaceutically acceptable salt thereof,
wherein
Values and alternative values for the variables in Structural Formula I are provided in the following paragraphs:
R1 is hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), nitro, cyano, hydroxy, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, (C1-C6)alkoxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, aryl(C1-C3)alkyl, heteroaryl(C1-C3)alkyl, cycloalkyl(C1-C3)alkyl, heterocyclyl(C1-C3)alkyl, hydroxy(C1-C3)alkyl, N(R7)2, C(═NOH)NH2, NR7CON(R7)2, CON(R7)2, CO2R7, COR8, OC(O)R7, SO2N(R7)2, SO2R8, NR7COR8, NR7CO2R8, NR7SO2R8 and OC(═O)N(R7)2, each optionally substituted with one or more groups represented by R6. Alternatively, R1 is hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C4)alkyl, or (C1-C4)alkoxy. Alternatively, R1 is chlorine.
R2 is hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), nitro, cyano, hydroxy, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, (C1-C6)alkoxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, aryl(C1-C3)alkyl, heteroaryl(C1-C3)alkyl, cycloalkyl(C1-C3)alkyl, heterocyclyl(C1-C3)alkyl, hydroxy(C1-C3)alkyl, N(R7)2, C(═NOH)NH2, NR7CON(R7)2, CON(R7)2, CO2R7, COR8, OC(O)R7, SO2N(R7)2, SO2R8, NR7COR8, NR7CO2R8, NR7SO2R8 and OC(═O)N(R7)2, each optionally substituted with one or more groups represented by R6. Alternatively, R2 is hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C4)alkyl, or (C1-C4)alkoxy. Alternatively, R2 is ethoxy. Alternatively, R2 is methoxy. Alternatively R2 is hydroxy.
R3 is hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), nitro, cyano, hydroxy, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, (C1-C6)alkoxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, aryl(C1-C3)alkyl, heteroaryl(C1-C3)alkyl, cycloalkyl(C1-C3)alkyl, heterocyclyl(C1-C3)alkyl, hydroxy(C1-C3)alkyl, N(R7)2, C(═NOH)NH2, NR7CON(R7)2, CON(R7)2, CO2R7, COR8, OC(O)R7, SO2N(R7)2, SO2R8, NR7COR8, NR7CO2R8, NR7SO2R8 and OC(═O)N(R7)2, each optionally substituted with one or more groups represented by R6. Alternatively, R3 is hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C4)alkyl, or (C1-C4)alkoxy. Alternatively, R3 is chlorine. Alternatively, R3 is fluorine. Alternatively, R3 is methoxy.
Alternatively, R2 and R3, along with the carbons to which they are attached, form a heterocyclyl or heteroaryl, wherein the heterocyclyl or heteroaryl formed is optionally substituted by one or more groups represented by R6.
R4 is hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), nitro, cyano, hydroxy, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, (C1-C6)alkoxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, aryl(C1-C3)alkyl, heteroaryl(C1-C3)alkyl, cycloalkyl(C1-C3)alkyl, heterocyclyl(C1-C3)alkyl, hydroxy(C1-C3)alkyl, N(R7)2, C(═NOH)NH2, NR7CON(R7)2, CON(R7)2, CO2R7, COR8, OC(O)R7, SO2N(R7)2, SO2R8, NR7COR8, NR7CO2R8, NR7SO2R8 and OC(═O)N(R7)2, each optionally substituted with one or more groups represented by R6. Alternatively, R4 is hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C4)alkyl, or (C1-C4)alkoxy.
R5 is aryl, heteroaryl, cycloalkyl, heterocyclyl, aryl(C1-C3)alkyl, aryl(C3-C10)heterocyclyl, aryl(C1-C3)alkoxy, heteroaryl(C1-C3)alkyl, cycloalkyl(C1-C3)alkyl, heterocyclyl(C1-C3)alkyl, alkylheteroaryl, (C1-C6)alkyl, (C1-C4)alkoxy, each optionally substituted with one to three groups represented by R6.
Each R6 is independently selected from halogen (e.g., fluorine, chlorine, bromine, iodine), nitro, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C3)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, aryl, haloaryl, cycloalkyl, aryl(C1-C3)alkyl, aryl(C1-C4)alkoxy, heterocyclyl, N(R7)2, C(═NOH)NH2, NR7CON(R7)2, CON(R7)2, CO2R7, COR8, OC(O)R8, S, SO2N(R8)2, SO2R8, SR8, S(C1-C3)alkylcycloalkyl, NR7COR8, NR7CO2R8, NR8SO2R8, S(═O)R8, —O-cycloalkyl, —O-heterocyclyl, adamantyl, OC(═O)N(R7)2,
Each R7 is independently selected from hydrogen, (C1-C10)alkyl, aryl, or aryl(C1-C3)alkyl, each optionally substituted with halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C3)alkoxy, (C1-C3)alkyl, halo(C1-C3)alkyl, halo(C1-C3)alkoxy, cyano or nitro; and
Each R8 is independently selected from hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C10)alkyl, (C1-C10)alkoxy, aryl, aryl(C1-C3)alkyl, cycloalkyl or aryl(C1-C3)alkoxy, each optionally substituted with halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C3)alkoxy, (C1-C3)alkyl, halo(C1-C3)alkyl, halo(C1-C3)alkoxy, cyano or nitro.
In another embodiment, the present invention is a method of treating a subject with malaria, comprising administering to the subject in need thereof an effective amount of a compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein values and alternative values for R1, R2, and R3 are as defined above for Structural Formula I, X is carbon or nitrogen and Y is carbon or nitrogen. Alternatively, X is carbon and Y is carbon. Alternatively, X is nitrogen and Y is carbon.
In another embodiment, the present invention is a method of treating a subject with malaria, comprising administering to the subject in need thereof an effective amount of a compound of Formula III:
or a pharmaceutically acceptable salt thereof, wherein values and alternative values for R1, R2, and R3 are as defined above for Structural Formula I.
In another embodiment, the present invention is a method of treating a subject with malaria, comprising administering to the subject in need thereof an effective amount of a compound of Formula (XXIII)
or a pharmaceutically acceptable salt thereof, wherein values and alternative values for R1, R2, and R3 are as defined above for Structural Formula I.
In another embodiment, the present invention is a method of treating a subject with malaria, comprising administering to the subject in need thereof an effective amount of a compound of Formula IV:
or a pharmaceutically acceptable salt thereof, wherein values and alternative values for R1 and R2 are as defined above for Structural Formula I.
In another embodiment, the present invention is a method of treating a subject with malaria, comprising administering to the subject in need thereof an effective amount of a compound of Formula V:
or a pharmaceutically acceptable salt thereof, wherein values and alternative values for R1 are as defined above for Structural Formula I.
Values and alternative values for the variables in Structural Formula IIa are provided in the following paragraphs:
X is carbon or nitrogen. Alternatively, X is carbon.
Y is carbon or nitrogen. Alternatively, Y is carbon.
R1a is hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), nitro, cyano, hydroxy, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, (C1-C6)alkoxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, aryl(C1-C3)alkyl, heteroaryl(C1-C3)alkyl, cycloalkyl(C1-C3)alkyl, heterocyclyl(C1-C3)alkyl, hydroxy(C1-C3)alkyl, N(R5a)2, C(═NOH)NH2, NR5aCON(R5a)2, CON(R5a)2, CO2R5a, COR6a, OC(O)R5a, SO2N(R5a)2, SO2R6a, NR5aCOR6a, NR5aCO2R6a, NR5aSO2R6a and OC(═O)N(R5a)2, each optionally substituted with one or more groups represented by R4a. Alternatively, R1a is halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C4)alkyl or (C1-C4)alkoxy. Alternatively, R1a is chlorine.
R2a is (C1-C6)alkyl, (C1-C6)alkoxy, S(C1-C6)alkyl, SO(C1-C6)alkyl, SO2(C1-C6)alkyl, optionally substituted with one or more groups represented by R4a. Alternatively, R2a is (C1-C6)alkoxy. Alternatively, R2a is ethoxy.
R3a is halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C6)alkyl or (C1-C6)alkoxy, each optionally substituted with one or more groups represented by R4a. Alternatively R3a is halogen. Alternatively, R3a is fluorine.
Each R4a is independently selected from halogen (e.g., fluorine, chlorine, bromine, iodine), nitro, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C3)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, aryl, haloaryl, cycloalkyl, aryl(C1-C3)alkyl, aryl(C1-C4)alkoxy, heterocyclyl, N(R5a)2, C(═NOH)NH2, NR5aCON(R5a)2, CON(R5a)2, CO2R5a, COR6a, OC(O)R5a, S, SO2N(R5a)2, SO2R6a, SR6a, S(C1-C3)alkylcycloalkyl, NR5aCOR6a, NR5CO2R6a, NR5aSO2R6a, S(═O)R6a, —O-cycloalkyl, —O-heterocyclyl, adamantyl, OC(═O)N(R5a)2,
and (C1-C3)alkylC(═O)NH(C1-C3)alkyl-O—(C1-C3)alkyl-O—(C1-C3)alkylNHR7a.
Each R5a is independently selected from hydrogen, (C1-C10)alkyl, aryl or aryl(C1-C6)alkyl, each optionally substituted with halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C3)alkoxy, (C1-C3)alkyl, halo(C1-C3)alkyl, halo(C1-C3)alkoxy, cyano or nitro.
Each R6a is independently selected hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C10)alkyl, (C1-C10)alkoxy, aryl(C1-C3)alkyl, cycloalkyl or aryl(C1-C3)alkoxy, each optionally substituted with halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C3)alkoxy, (C1-C3)alkyl, halo(C1-C3)alkyl, halo(C1-C3)alkoxy, cyano or nitro.
In another embodiment, the present invention is a compound of Formula IIIa:
or a pharmaceutically acceptable salt thereof, wherein values and alternative values for R1a, R2a and R3a and are as defined above for Formula IIa.
In another embodiment, the present invention is a compound of Formula XXIIIa:
or a pharmaceutically acceptable salt thereof, wherein values and alternative values for R1a, R2a and R3a and are as defined above for Formula IIa.
In another embodiment, R1, R2, R3 and R4 are independently hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C4)alkyl, or (C1-C4)alkoxy and the remainder of variables are as defined above for Formula I.
In another embodiment, R3 is chlorine and the remainder of variables are as defined above for Formula I.
In another embodiment, R1 is chlorine, R2 is ethoxy, R3 is fluorine, X is carbon, Y is carbon and the remainder of variables are as defined above for Formula II.
In another embodiment, R1 is chlorine, R2 and R3 are methoxy, X is nitrogen, Y is carbon and the remainder of variables are as defined above for Formula II.
In another embodiment, R1 is chlorine, R2 is hydroxyl, R3 is fluorine and the remainder of variables are as defined above for Formula II.
In another embodiment, R1 is chlorine, R2 is hydroxyl, R3 is fluorine, X is carbon, Y is carbon and the remainder of variables are as defined above for Formula II.
In another embodiment, R1 is chlorine, R2 ethoxy and R3 is fluorine and the remainder of variables are as defined above for Formula III.
In another embodiment, R1 is chlorine and the remainder of variables are as defined above for Formula V.
In another embodiment, R1a is halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C4)alkyl or (C1-C4)alkoxy and the remainder of variables are as defined above for Formula IIa.
In another embodiment, R1a (C1-C4)alkoxy and the remainder of variables are as defined above for Formula IIa.
In another embodiment, R1a is halogen and the remainder of variables are as defined above for Formula IIa.
In another embodiment, R1a is chlorine, R2a and R3a are methoxy, X is nitrogen, Y is carbon and the remainder of variables are as defined above for Formula IIa.
In another embodiment, R1b is halogen, (C1-C6)alkyl or (C1-C6)alkoxy and the remainder of variables are as defined above for Formula VI.
In another embodiment, R1b is halogen and the remainder of variables are as defined above for Formula VI.
In another embodiment, R1b is chlorine and the remainder of variables are as defined above for Formula VI.
In another embodiment, R1b is methyl and the remainder of variables are as defined above for Formula VI.
In another embodiment, R1b is methoxy and the remainder of variables are as defined above for Formula VI.
Specific examples of compounds of the invention, and their respective IC50 values, are presented in Table 1. Compounds disclosed in Table 1 are encompassed by the scope of the invention.
The compounds of the invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the salts of the compounds of the invention refer to non-toxic “pharmaceutically acceptable salts.” Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
Pharmaceutically acceptable acidic/anionic salts include, the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, malonate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, hydrogensulfate, tannate, tartrate, teoclate, tosylate, and triethiodide salts.
Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, N-methyl-D-glucamine, L-arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.
The disclosed compounds can be used alone (i.e. as a monotherapy) or in combination with another therapeutic agent effective for treating malaria.
Alternatively, a pharmaceutical composition of the invention may comprise an antimalarial compound disclosed herein or a pharmaceutical salt thereof, as the only pharmaceutically active agent in the pharmaceutical composition. The disclosed antimalarial compounds can be used alone or in a combination therapy with one or more additional agents for the treatment of malaria.
A pharmaceutical composition of the invention may, alternatively or in addition to an antimalarial compound disclosed herein comprise a pharmaceutically acceptable salt of an antimalarial compound disclosed herein or a prodrug or pharmaceutically active metabolite of such a compound or salt and one or more pharmaceutically acceptable carriers therefore. Alternatively, a pharmaceutical composition of the invention may comprise an antimalarial compound disclosed herein or a pharmaceutical salt thereof as the only pharmaceutically active agent in the pharmaceutical composition.
The invention includes a therapeutic method for treating malaria in a subject in need thereof comprising administering to the subject in need thereof an effective amount of an antimalarial compound disclosed herein or a pharmaceutically acceptable salt thereof or a composition thereof (e.g., a pharmaceutical composition comprising an antimalarial compound and a pharmaceutically-acceptable carrier). Compounds disclosed herein can be used in the treatment of malaria. Thus, in one embodiment, the invention relates to the use of a compound disclosed herein for the treatment of malaria in a subject in need thereof. In other embodiments, the invention relates to the use of a compound disclosed herein in the treatment of malaria and the use of a compound disclosed herein in the manufacture of a medicament for the treatment of malaria. As used herein, “treating” or “treatment” includes both therapeutic and prophylactic treatment. Therapeutic treatment includes reducing the symptoms associated with a disease or condition and/or increasing the longevity of a subject with the disease or condition. Prophylactic treatment includes delaying the onset of a disease or condition in a subject at risk of developing the disease or condition or reducing the likelihood that a subject will then develop the disease or condition in a subject that is at risk for developing the disease or condition.
As used herein, an “effective amount” is an amount sufficient to achieve a desired effect under the conditions of administration, in vitro, in vivo or ex vivo, such as, for example, an amount sufficient to treat malaria in a subject. The effectiveness of a compound can be determined by suitable methods known by those of skill in the art including those described herein.
As defined herein, a “therapeutically effective amount” is an amount sufficient to achieve a desired therapeutic or prophylactic effect in a subject in need thereof under the conditions of administration, such as, for example, an amount sufficient treat malaria in a subject. The effectiveness of a therapy can be determined by suitable methods known by those of skill in the art.
An embodiment of the invention includes administering an antimalarial compound disclosed herein, or composition thereof, in a combination therapy with one or more additional agents for the treatment of malaria. Agents for the treatment of malaria include quinine, atovaquone, chloroquine, cycloguanil, hydroxychloroquine, amodiaquine, pyrimethamine, sulphadoxine, proguanil, mefloquine, halofantrine, pamaquine, primaquine, artemisinin, artemether, artesunate, artenimol, lumefantrine, dihydroartemisinin, piperaquine, artether, doxycycline and clindamycin.
The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Additionally, the compounds of the present invention can be administered intranasally or transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active ingredient, either compounds or a corresponding pharmaceutically acceptable salt of a compound of the present invention.
For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can either be solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active ingredient.
In tablets, the active ingredient is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
The powders and tablets preferably contain from about one to about seventy percent of the active ingredient. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low-melting wax, cocoa butter, and the like. Tablets, powders, cachets, lozenges, fast-melt strips, capsules and pills can be used as solid dosage forms containing the active ingredient suitable for oral administration.
Suitable for enteral administration are also suppositories that consist of a combination of the active ingredient and a suppository base. Suitable as suppository bases are, for example, natural or synthetic triglycerides, paraffins, polyethylene glycols or higher alkanols. It is also possible to use gelatin rectal capsules that contain a combination of the active ingredient and a base material; suitable base materials are, for example, liquid triglycerides, polyethylene glycols or paraffin hydrocarbons. For preparing suppositories, a low-melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first-melted and the active ingredient is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
Liquid form preparations include solutions, suspensions, retention enemas, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
Aqueous solutions suitable for oral administration can be prepared by dissolving the active ingredient in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired. Aqueous suspensions for oral administration can be prepared by dispersing the finely divided active ingredient in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
The pharmaceutical composition is preferably in unit dosage form. In such form, the composition is subdivided into unit doses containing appropriate quantities of the active ingredient. The unit dosage form can be a packaged preparation, the package containing discrete quantities of, for example, tablets, powders, and capsules in vials or ampules. Also, the unit dosage form can be a tablet, cachet, capsule, or lozenge itself, or it can be the appropriate amount of any of these in packaged form.
The dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill in the art. Also, the pharmaceutical composition may contain, if desired, other compatible therapeutic agents.
As described herein, it has been found that 2-aminoindole compounds of the invention can be produced by aminating a 2-oxindole compound with tert-butyldimethylsilyl amine (TBDMSNH2), for example, in the presence of SnCl4 and an agent selected from triethylamine, N-ethyldiisopropylamine or N-methyl morpholine (NMM). It has also been found that aminating 2-oxindole compounds with TBDMSNH2 preserves stereospecificity. Thus, in a further embodiment, the invention relates to methods of aminating a 2-oxindole compound to produce a 2-aminoindole compound using tert-butyldimethylsilyl amine (TBDMSNH2) in the presence of SnCl4 and an agent selected from triethylamine, N-ethyldiisopropylamine or N-methyl morpholine (NMM). Representative schemes for such a method are described herein in Examples 8-10, Schemes 20-22.
In a particular embodiment, TBDMSNH2 is used in an enantioselective method of preparing a 2-aminoindole. A representative scheme for such a method is described herein in Example 10, Scheme 22.
In one embodiment, the invention relates to a method of preparing a compound represented by Formula VII:
or a pharmaceutically acceptable salt thereof,
wherein
A representative scheme for such a method is described herein in Example 8, Scheme 20.
In an additional embodiment, the invention relates to a method of preparing a compound represented by Formula XVII:
wherein the method comprises:
In a particular embodiment, the amination step in the synthetic methods described herein is performed at a temperature of about 120° C. (e.g., in a microwave) for about 40 to about 60 minutes in the presence of tetrahydrofuran (THF).
As an alternative to the enantioselective amination step described herein, chiral separation techniques and/or methods can be employed to prepare enantiomers of 2-aminoindole compounds. Suitable chiral separation techniques and methods include, for example, various well-known chiral chromatography techniques and separation methods. An appropriate technique and/or method of separating enantiomers from a racemic mixture of a 2-aminoindole compound disclosed herein can be readily determined by those of skill in the art.
A representative scheme for such a method is described herein in Example 10, Scheme 22.
In addition to the methods described above, supercritical fluid chromatography techniques and/or methods can be employed to prepare enantiomers of 2-aminoindole compounds, as described in Example 18.
In another embodiment, the present invention is a method of preparing a compound represented by Formula VII:
or a pharmaceutically acceptable salt thereof,
wherein
and
A representative scheme for such a method is described herein in Example 8, Scheme 20.
In another embodiment, the instant invention is a method of preparing a compound represented by Formula XI:
or a pharmaceutically acceptable salt thereof,
wherein
and
and
and
A representative scheme for such a method is described herein in Example 9, Scheme 21.
In another embodiment, the instant invention is a method of preparing a compound represented by Formula XVII:
or a pharmaceutically acceptable salt thereof,
wherein
and
and
A representative scheme for such a method is described herein in Example 10, Scheme 22.
Values and alternative values for the variables in Structural Formula VI-XXI are provided in the following paragraphs:
R1b is hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), nitro, cyano, hydroxy, (C1-C6)alkyl, (C1-C6)alkenyl, (C1-C6)alkynyl, (C1-C6)alkoxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, aryl(C1-C3)alkyl, heteroaryl(C1-C3)alkyl, cycloalkyl(C1-C3)alkyl, heterocyclyl(C1-C3)alkyl, hydroxy(C1-C3)alkyl, N(R3b)2, C(═NOH)NH2, NR3CON(R3b)2, CON(R3b)2, CO2R3b, COR4b, OC(O)R3b, SO2N(R3b)2, SO2R4b, NR3COR4b, NR3bCO2R4b, NR3bSO2R4b and OC(═O)N(R3b)2, each optionally substituted with one or more groups represented by R2b. Alternatively, R1b is halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C6)alkyl or (C1-C6)alkoxy. Alternatively, R1b is halogen. Alternatively, R1b is chlorine. Alternatively, R1b is methyl. Alternatively, R1b is methoxy.
Each R2b is independently selected from halogen (e.g., fluorine, chlorine, bromine, iodine), nitro, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C3)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, aryl, haloaryl, cycloalkyl, aryl(C1-C3)alkyl, aryl(C1-C4)alkoxy, heterocyclyl, N(R3b)2, C(═NOH)NH2, NR3bCON(R3b)2, CON(R3b)2, CO2R3b, COR4b, OC(O)R3b, S, SO2N(R3b)2, SO2R4b, SR4b, S(C1-C3)alkylcycloalkyl, NR3bCOR4b, NR3bCO2R4b, NR3aSO2R4a, S(═O)R3b, —O-cycloalkyl, —O-heterocyclyl, adamantyl, OC(═O)N(R3b)2,
Each R3b is independently selected from hydrogen, (C1-C10)alkyl, aryl or aryl(C1-C3)alkyl, each optionally substituted with halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C3)alkoxy, (C1-C3)alkyl, halo(C1-C3)alkyl, halo(C1-C3)alkoxy, cyano or nitro; and
Each R4b is independently selected from hydrogen, halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C10)alkyl, (C1-C10)alkoxy, aryl, aryl(C1-C3)alkyl, cycloalkyl or aryl(C1-C3)alkoxy, each optionally substituted with halogen (e.g., fluorine, chlorine, bromine, iodine), (C1-C3)alkoxy, (C1-C3)alkyl, halo(C1-C3)alkyl, halo(C1-C3)alkoxy, cyano or nitro.
The term “alkyl”, used alone or as part of a larger moiety such as “arylalkyl” or “haloalkyl” means a straight or branched hydrocarbon radical having 1-10 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, i-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.
An “alkenyl group” is an alkyl group in which at least a pair of adjacent methylenes are replaced with —CH═CH—.
An “alkynyl group” is an alkyl group in which at least a pair of adjacent methylenes are replaced with —C≡C—.
The term “cycloalkyl”, used alone or as part of a larger moiety, means a monocyclic, bicyclic or tricyclic, saturated hydrocarbon ring having 3-10 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1]heptyl, Spiro[4.4]nonane, adamantyl and the like. Unless otherwise described, exemplary substituents for a substituted cycloalkyl group include groups represented by R6.
“Aryl”, used alone or as part of a larger moiety as in “arylalkyl”, “arylalkoxy”, or “aryloxyalkyl”, means a 6-14 membered carbocyclic aromatic monocyclic or polycyclic ring system. Examples include phenyl, naphthyl, anthracenyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, fluorenyl, indanyl, indenyl and the like. The term “aryl” also includes phenyl rings fused to a non-aromatic carbocyclic ring, a heterocyclyl group or to a heteroaryl group, wherein the connection to an indole ring from structural Formula (I) is through the phenyl ring of the fused ring system and includes, for example dibenzo[b,d]furyl, quinoline, or the like. The term “aryl” may be used interchangeably with the terms “aromatic group”, “aryl ring” “aromatic ring”, “aryl group” and “aromatic group”. Unless otherwise described, exemplary substituents for a substituted aryl group include groups represented by R6.
“Hetero” refers to the replacement of at least one carbon atom member in a ring system with at least one heteroatom selected from N, S, and O. A hetero ring may have 1, 2, 3, or 4 carbon atom members replaced by a heteroatom.
“Heteroaryl”, used alone or as part of a larger moiety as in “heteroarylalkyl” or “heteroarylalkoxy”, means a 5-10 membered monovalent heteroaromatic monocyclic and polycyclic ring radical containing 1 to 4 heteroatoms independently selected from N, O, and S. The term “heteroaryl” also includes monocyclic heteroaryl ring fused to non-aromatic carbocyclic ring, to a heterocyclyl group or to an aryl ring, wherein the connection to a indole ring of structural Formula (I) is through the monocyclic heteroaryl ring of the fused ring system. Heteroaryl groups include, but are not limited to, furyl, thienyl, thiophenyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridinyl-N-oxide, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, indolyl, isoindolyl, imidazo[4,5-b]pyridine, benzo[b]furyl, benzo[b]thienyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzodioxolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, cinnolinyl, phthalzinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-oxadiazolyl, 1,2,5-thiadiazolyl, 1,2,5-thiadiazolyl-1-oxide, 1,2,5-thiadiazolyl-1,1-dioxide, 1,3,4-thiadiazolyl, 1,2,4-triazinyl, 1,3,5-triazinyl, tetrazolyl, and pteridinyl. The terms “heteroaryl”, “heteroaromatic”, “heteroaryl ring”, “heteroaryl group” and “heteroaromatic group” are used interchangeably herein. “Heteroarylalkyl” means alkyl substituted with heteroaryl; and “heteroarylalkoxy” means alkoxy substituted with heteroaryl. Unless otherwise described, exemplary substituents for a substituted heteroaryl group include the include groups represented by R6.
The term “heterocyclyl” means a 4-, 5-, 6- and 7-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S. Exemplary heterocyclyls include azetidine, pyrrolidine, pyrrolidin-2-one, 1-methylpyrrolidin-2-one, piperidine, piperidin-2-one, 2-pyridone, 4-pyridone, piperazine, 1-(2,2,2-trifluoroethyl)piperazine, piperazin-2-one, 5,6-dihydropyrimidin-4-one, pyrimidin-4-one, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, tetrahydrothiopyran, isoxazolidine, 1,3-dioxolane, 1,3-dithiolane, 1,3-dioxane, 1,4-dioxane, 1,3-dithiane, 1,4-dithiane, oxazolidin-2-one, imidazolidin-2-one, imidazolidine-2,4-dione, tetrahydropyrimidin-2(1H)-one, morpholine, N-methylmorpholine, morpholin-3-one, 1,3-oxazinan-2-one, thiomorpholine, thiomorpholine 1,1-dioxide, tetrahydro-1,2,5-thiaoxazole 1,1-dioxide, tetrahydro-2H-1,2-thiazine 1,1-dioxide, hexahydro-1,2,6-thiadiazine 1,1-dioxide, tetrahydro-1,2,5-thiadiazole 1,1-dioxide and isothiazolidine 1,1-dioxide. Unless otherwise described, exemplary substituents for a substituted heterocyclyl group include groups represented by R6.
The term “alkoxy” means an alkyl radical attached through an oxygen linking atom. “(C1-C4)-alkoxy” includes methoxy, ethoxy, propoxy, and butoxy.
The term “cycloalkoxy” means a cycloalkyl radical attached through an oxygen linking atom. “(C3-C6)cycloalkoxy” includes cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.
The term “aryloxy” means an aryl moiety attached through an oxygen linking atom. Aryloxy includes, but not limited to, phenoxy.
The terms “halogen” and “halo” are interchangeably used herein and each refers to fluorine, chlorine, bromine, or iodine.
As used herein the terms “subject” and “patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like). Typically, the subject is a human in need of treatment.
Malaria is a parasitic infection of red blood cells caused by eukaryotic protists of the genus Plasmodium in the phylum Apicomplexa. Human malaria is known to be caused by five different Plasmodium species: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae or Plasmodium knowlesi. Malaria parasites are transmitted by female Anopheles mosquitoes. The parasites multiply within red blood cells, causing symptoms that include symptoms of anemia (light headedness, shortness of breath, tachycardia), as well as other general symptoms such as an enlarged spleen, fatigue, fever, chills, nausea, flu-like illness, and in severe cases, coma and death. The methods described herein are useful for treating human malaria caused by a Plasmodium species, such as Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae or Plasmodium knowlesi. In a particular embodiment, the invention relates to a method of treating a malaria caused by Plasmodium falciparum. Both drug-resistant and drug-sensitive strains of Plasmodium are intended to be included herein.
Certain of the disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center. “Enantiomer” means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms. The symbol “*” in a structural formula represents the presence of a chiral carbon center. “R” and “S” represent the configuration of substituents around one or more chiral carbon atoms. Thus, “R*” and “S*” denote the relative configurations of substituents around one or more chiral carbon atoms. Enantiomers of a compound can be prepared, for example, by separating an enantiomer from a racemate using one or more well-known techniques and methods, such as, for example, chiral chromatography and separation methods based thereon. The appropriate technique and/or method for separating an enantiomer of a compound described herein from a racemic mixture can be readily determined by those of skill in the art.
“Racemate” or “racemic mixture” means a compound containing two enantiomers, wherein such mixtures exhibit no optical activity; i.e., they do not rotate the plane of polarized light.
“Geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Atoms (other than H) on each side of a carbon-carbon double bond may be in an E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration.
“R,” “S,” “S*,” “R*,” “E,” “Z,” “cis,” and “trans,” indicate configurations relative to the core molecule.
Certain of the disclosed compounds may exist in various tautomeric forms. Tautomeric forms exist when a compound is a mixture of two or more structurally distinct compounds that are in rapid equilibrium. Certain compounds of the invention exist as tautomeric forms. For example, the following compound represented by Structural Formula (A) and (B) include at least the following tautomers forms:
It is to be understood that when one tautomeric form of a compound is depicted by name or structure, all tautomeric forms of the compound are included.
Certain of the disclosed compounds may exist in atropisomeric forms. Atropisomers are stereoisomers resulting from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers.
The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include forming the salt of a free base of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the isomers of an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either a starting material or a final product using various well known chromatographic methods.
When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. Percent optical purity by weight is the ratio of the weight of the enantiomer over the weight of the enantiomer plus the weight of its optical isomer.
When a disclosed compound is named or depicted by structure without indicating the stereochemistry, and the compound has at least one chiral center, it is to be understood that the name or structure encompasses either enantiomer of the compound free from the corresponding optical isomer, a racemic mixture of the compound and mixtures enriched in one enantiomer relative to its corresponding optical isomer.
When a disclosed compound is named or depicted by structure without indicating the stereochemistry and has at least two chiral centers, it is to be understood that the name or structure encompasses a diastereomer free of other diastereomers, a pair of diastereomers free from other diastereomeric pairs, mixtures of diastereomers, mixtures of diastereomeric pairs, mixtures of diastereomers in which one diastereomer is enriched relative to the other diastereomer(s) and mixtures of diastereomeric pairs in which one diastereomeric pair is enriched relative to the other diastereomeric pair(s).
As used herein, “substantially pure” means that the depicted or named compound is at least about 60% by weight. For example, “substantially pure” can mean about 60%, 70%, 72%, 75%, 77%, 80%, 82%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or a percentage between 70% and 100%. In one embodiment, substantially pure means that the depicted or named compound is at least about 75%. In a specific embodiment, substantially pure means that the depicted or named compound is at least about 90% by weight.
All solvents for reactions, extractions, and chromatography were of analytical grade. Dichloromethane, N,N-dimethylformamide, methanol, and tetrahydrofuran were passed through an alumina column (A-2) and supported copper redox catalyst (Q-5 reactant). All other solvents, except for ethanol (Pharmco-Aaper), were obtained from Aldrich. Solvents were used without further purification, except where noted.
Reaction vessels were oven-dried for at least 12 hours, and reactions took place in either argon or nitrogen atmospheres. All reactions were magnetically stirred.
Reactions were monitored by thin layer chromatography (TLC) using silica gel 60 plates, treated with 254 nm-fluorescent dye (EMD) and by LC-MS (Waters 2690 Separations Module with Waters Micromass LCT or Waters 2795 Separations Module with Waters Micromass ZQ). Stated mass spectrometry data are from LC-MS analysis.
Evaporation of solvent was conducted by rotary evaporation. For column chromatography purification, silica gel 60, 230-400 mesh was used (EMD). Flash purification systems were also used with associated pre-packaged silica columns (Biotage Isolera and Teledyne Isco Companion).
1H NMR spectra were recorded at 300 or 500 MHz on Bruker 300 and Varian I-500 NMR spectrometers, respectively. 13C NMR spectra were recorded at 126 MHz using a Varian I-500 NMR spectrometer. Chemical shifts in CDCl3, CD3OD, CD3CN, and (CD3)2O are reported in ppm, relative to CHCl3 (1H NMR, δ=7.24 ppm; 13C NMR, δ=77.23 ppm), CH3OH (1H NMR, δ=4.87 ppm, 3.31 ppm; 13C NMR, δ=49.15 ppm), CH3CN (1H NMR, δ=1.94), and (CH3)2O (1H NMR, δ=2.05). Coupling constants are given in hertz. Attempts were made to be consistent in the NMR solvent; however, varying solubilities of compounds demanded the use of different solvents. Suitable solvents can be ascertained by those of skill in the art.
All solvents for reactions, extractions, and chromatography were of analytical grade. Dichloromethane, N,N-dimethylformamide, methanol, and tetrahydrofuran were passed through an alumina column (A-2) and supported copper redox catalyst (Q-5 reactant). All other solvents, except for ethanol (Pharmco-Aaper), were obtained from Aldrich. Solvents were used without further purification, except where noted.
Reaction vessels were oven-dried for at least 12 hours, and reactions took place in either argon or nitrogen atmospheres. All reactions were magnetically stirred.
Reactions were monitored by thin layer chromatography (TLC) using silica gel 60 plates, treated with 254 nm-fluorescent dye (EMD) and by LC-MS (Waters 2690 Separations Module with Waters Micromass LCT or Waters 2795 Separations Module with Waters Micromass ZQ). Stated mass spectrometry data are from LC-MS analysis.
Evaporation of solvent was conducted by rotary evaporation. For column chromatography purification, silica gel 60, 230-400 mesh was used (EMD). Flash, purification systems were also used with associated pre-packaged silica columns (Biotage Isolera and Teledyne Isco Companion).
1H NMR spectra were recorded at 300 or 500 MHz on Bruker 300 and Varian I-500 NMR spectrometers, respectively. 13C NMR spectra were recorded at 126 MHz using a Varian I-500 NMR spectrometer. Chemical shifts in CDCl3, CD3OD, CD3CN, and (CD3)2O are reported in ppm, relative to CHCl3 (1H NMR, δ=7.24 ppm; 13C NMR, δ=77.23 ppm), CH3OH (1H NMR, δ=4.87 ppm, 3.31 ppm; 13C NMR, δ=49.15 ppm), CH3CN (1H NMR, δ=1.94), and (CH3)2O (1H NMR, δ=2.05). Coupling constants are given in hertz. Attempts were made to be consistent in the NMR solvent; however, varying solubilities of compounds demanded the use of different solvents.
All solvents for reactions, extractions, and chromatography were of analytical grade. Dichloromethane, N,N-dimethylformamide, methanol, and tetrahydrofuran were passed through an alumina column (A-2) and supported copper redox catalyst (Q-5 reactant). All other solvents, except for ethanol (Pharmco-Aaper), were obtained from Aldrich. Solvents were used without further purification, except where noted.
Reaction vessels were oven-dried for at least 12 hours, and reactions took place in either argon or nitrogen atmospheres. All reactions were magnetically stirred.
Reactions were monitored by thin layer chromatography (TLC) using silica gel 60 plates, treated with 254 nm-fluorescent dye (EMD) and by LC-MS (Waters 2690 Separations Module with Waters Micromass LCT or Waters 2795 Separations Module with Waters Micromass ZQ). Stated mass spectrometry data are from LC-MS analysis.
Evaporation of solvent was conducted by rotary evaporation. For column chromatography purification, silica gel 60, 230-400 mesh was used (EMD). Flash purification systems were also used with associated pre-packaged silica columns (Biotage Isolera and Teledyne Isco Companion).
1H NMR spectra were recorded at 300 or 500 MHz on Bruker 300 and Varian I-500 NMR spectrometers, respectively. 13C NMR spectra were recorded at 126 MHz using a Varian I-500 NMR spectrometer. Chemical shifts in CDCl3, CD3OD, CD3CN, and (CD3)2O are reported in ppm, relative to CHCl3 (1H NMR, δ=7.24 ppm; 13C NMR, δ=77.23 ppm), CH3OH (1H NMR, δ=4.87 ppm, 3.31 ppm; 13C NMR, δ=49.15 ppm), CH3CN (1H NMR, δ=1.94), and (CH3)2O (1H NMR, δ=2.05). Coupling constants are given in hertz. Attempts were made to be consistent in the NMR solvent; however, varying solubilities of compounds demanded the use of different solvents.
2-amino-5-iodobenzoic acid (500 mg, 1.9 mmol, 1 eq.) was dissolved in nitrogen-degassed THF (10 mL) at room temperature. TMS-acetylene (0.34 mL, 2.5 mmol, 1.3 eq.), nitrogen-degassed triethylamine (0.8 mL, 5.7 mmol, 3 eq.), dichloro-bis(triphenylphosphine)palladium(II) (267 mg, 0.4 mmol, 0.2 eq.), and copper iodide (145 mg, 0.8 mmol, 0.4 eq.) were added, in order, to the reaction in the dark. The reaction was then stirred at room temperature for 20 minutes. The solvent was evaporated, and the residue was purified on silica column (DCM/MeOH, 39:1→19:1) to result in 315 mg (71%) of the title compound as a dark orange solid. 1H NMR (500 MHz, CDCl3) δ 8.07 (d, J=1.7, 1H, Ar—H), 7.37 (dd, J=1.8, 8.6, 1H, Ar—H), 6.57 (d, J=8.6, 1H, Ar—H), 0.22 (s, 9H, SiC3H9). 13C NMR (126 MHz, CDCl3) δ 173.11 (COOH), 151.15 (C—Ar), 138.41 (C—Ar), 136.64 (C—Ar), 116.94 (C—Ar), 111.06 (C—Ar), 109.23 (C—Ar), 104.98 (CSi(CH3)3), 92.02 (CCSi(CH3)3), 0.29 (Si(CH3)3). Exact Mass, 233.09. 231.7418 [M−H]−, 233.7569 [M+H]+.
2-amino-5-[2-(trimethylsilyl)ethynyl]benzoic acid (630 mg, 2.7 mmol, 1 eq.), HBTU (1.54 g, 4.0 mmol, 1.5 eq.), and 4-methylmorpholine (0.74 mL, 6.7 mmol, 2.5 eq.) were added, in order, to DMF (10 mL) and stirred at room temperature for 10 minutes. N,O-dimethylhydroxylamine hydrochloride (290 mg, 3.0 mmol, 1.1 eq.) was then added to the reaction, and the reaction was stirred at room temperature for 16 hours. Water was then added (20 mL), and the reaction was extracted three times with ethyl acetate (50 mL each). To remove residual water, saturated sodium chloride (20 mL) was added to the organic layer, and the organic layer was separated and dried over sodium sulfate. The solvent was evaporated by rotary evaporation, and the residue was purified on silica column (hexanes/ethyl acetate, 3:1) to result in 320 mg (43%) of the title compound as an orange solid. 1H NMR (500 MHz, CDCl3) δ 8.38 (d, J=1.5, 1H, Ar—H), 7.82 (dd, J=1.5, 7.5, 1H, AR—H), 7.10 (d, J=7.3, 1H, Ar—H), 5.61 (s, 2H, NH2), 4.09 (s, 3H, OCH3), 3.66 (s, 3H, NCH3), 0.22 (s, 9H, Si(CH3)3). 13C NMR (126 MHz, CDCl3) δ 169.20 (CON), 147.35 (C—Ar), 135.24 (C—Ar), 133.50 (C—Ar), 116.65 (C—Ar), 116.55 (C—Ar), 111.21 (C—Ar), 105.40 (CSi(CH3)3), 91.90 (CCSi(CH3)3), 61.44 (NOCH3), 34.53 (NCH3), 0.29 (Si(CH3)3). Exact Mass, 276.13. 277.1046 [M+H]+.
2-amino-N-methoxy-N-methyl-5-[2-(trimethylsilyl)ethynyl]benzamide (403 mg, 1.5 mmol, 1 eq.) and 3-(4-bromophenyl)-3-(trifluoromethyl)-1,2-bis(trimethylsilyl)diaziridine (synthesized by a 5-step process: Bender et al., 2007, 599 mg, 1.5 mmol, 1 eq.) were added together in a round-bottom flask and purged with nitrogen. THF was added, and the reaction was stirred at room temperature until all solids dissolved. The reaction was then cooled to −80° C. in a diethyl ether/dry ice bath, and 2.5 M n-butyllithium in hexanes (1.0 mL, 2.6 mmol, 1.8 eq.) was added, causing the reaction to turn a dark red color. The reaction was stirred at −80° C. for 2 hours and then quenched with saturated ammonium chloride solution (20 mL). The quenched reaction was extracted three times with ethyl acetate (50 mL each). The organic layer was then dried over sodium sulfate, and the solvent was evaporated. Purification on silica column (hexanes/ethyl acetate, 3:1→1:1) resulted in 342 mg (58%) of the title compound as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.69 (dd, J=8.2, 37.0, 4H, Ar—H), 7.50 (d, J=1.8, 1H, Ar—H), 7.37 (dd, J=1.9, 8.6, 1H, Ar—H), 6.65 (d, J=8.6, 1H, Ar—H), 6.32 (s, 2H, NH2), 2.88 (d, J=8.6, 1H, CNH), 2.32 (d, J=8.8, 1H, CNH), 0.18 (s, 9H, Si(CH3)3). 13C NMR (126 MHz, CDCl3) δ 197.58 (CO), 151.25 (C—Ar), 141.43 (C—Ar), 138.23 (C—Ar), 138.06 (C—Ar), 134.66 (C—Ar), 129.57 (C—Ar), 128.37 (q, C—Ar, J=0.57), 123.55 (q, J=278.40, CF3), 117.35 (C—Ar), 117.19 (C—Ar), 110.28 (C—Ar), 104.90 (CSi(CH3)3), 92.18 (CCSi(CH3)3), 58.05 (q, J=36.3, C(NH)2), 0.25 (Si(CH3)3). Exact Mass, 403.13. 402.1046 [M−H]−, 404.1982 [M+H]+.
2-({4-[3-(trifluoromethyl)diaziridin-3-yl]phenyl}carbonyl)-4-[2-(trimethylsilyl)ethynyl]aniline (66 mg, 0.16 mmol, 1 eq.) was dissolved in diethyl ether (10 mL) and manganese(IV) oxide (300 mg, 3.4 mmol, 21 eq.) was added to the solution. The reaction was stirred at room temperature for 30 minutes and then filtered through Celite with DCM to remove the manganese(IV) oxide. The solvent was evaporated, and the residue was purified on silica column (hexanes/ethyl acetate, 9:1→2:1), resulting in 64 mg (97%) of the title compound as a yellow-orange solid. 1H NMR (500 MHz, CDCl3) δ 7.63 (d, J=8.4, 2H, Ar—H), 7.46 (d, J=1.7, 1H, Ar—H), 7.37 (dd, J=1.8, 8.6, 1H, Ar—H), 7.28 (d, J=8.2, 2H, Ar—H), 6.64 (d, J=8.6, 1H, Ar—H), 6.30 (s, 2H, NH2), 0.18 (s, 9H, Si(CH3)3). 13C NMR (126 MHz, CDCl3) δ 197.20 (CO), 151.24 (C—Ar), 140.72 (C—Ar), 138.19 (C—Ar), 137.94 (C—Ar), 132.27 (C—Ar), 129.59 (C—Ar), 126.48 (q, C—Ar, J=1.19), 122.13 (q, J=274.80, CF3), 117.35 (C—Ar), 117.10 (C—Ar), 110.28 (C—Ar), 104.86 (CSi(CH3)3), 92.21 (CCSi(CH3)3), 28.62 (q, J=40.69, CN2), 0.22 (Si(CH3)3). Exact Mass, 401.12. 399.7011 [M−H]−, 401.7108 [M+H]+.
2-({4-[3-(trifluoromethyl)diazirin-3-yl]phenyl}carbonyl)-4-[2-(trimethylsilyl)ethynyl]aniline (47 mg, 0.12 mmol, 1 eq.) was dissolved in DCM (10 mL) and cooled to 0° C. Dichloroacetyl chloride (0.013 mL, 0.14 mmol, 1.15 eq.) was then added, and the reaction was stirred at 0° C. for 10 minutes. The reaction was then warmed to room temperature and stirred for 30 minutes. The solvent was evaporated, and the residue was purified by silica column (hexanes/ethyl acetate, 3:1), resulting in 57 mg (94%) of the title compound as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 11.83 (s, 1H, CHCl2), 8.56 (d, J=8.7, 1H, Ar—H), 7.76 (d, J=9.1, 2H, Ar—H), 7.69 (dd, J=1.5, 8.8, 1H, Ar—H), 7.61 (d, J=1.8, 1H, Ar—H), 7.32 (d, J=8.2, 2H, Ar—H), 6.03 (s, 1H, NH), 0.19 (s, 9H, Si(CH3)3). 13C NMR (126 MHz, CDCl3) δ 197.81 (Ar2—CO), 163.13 (NCOC), 139.23 (C—Ar), 138.79 (C—Ar), 138.33 (C—Ar), 136.61 (C—Ar), 134.08 (C—Ar), 130.47 (C—Ar), 126.71 (q, J=1.23, C—Ar), 123.41 (C—Ar), 122.03 (q, J=274.68, CF3), 121.60 (C—Ar), 120.94 (C—Ar), 103.04 (CSi(CH3)3), 96.22 (CCSi(CH3)3), 67.16 (CCl2), 28.64 (q, J=40.83, CN2), 0.03 (Si(CH3)3). Exact Mass, 511.05. 509.4841 [M−H]−, 511.487 [M+H]+.
2,2-dichloro-N-[2-({4-[3-(trifluoromethyl)diazirin-3-yl]phenyl}carbonyl)-4-[2-(trimethylsilyl)ethynyl]phenyl]acetamide (57 mg, 0.11 mmol, 1 eq.) was dissolved in EtOH (3 mL). Potassium cyanide (9.4 mg, 0.14 mmol, 1.3 eq.) in water (1 mL) was added to the reaction, and the reaction was stirred at room temperature for 16 hours. The EtOH was evaporated, and additional water (8 mL) was added. The reaction was then extracted three times with 5% isopropanol in DCM (20 mL each), and the organic layer was dried over sodium sulfate. The solvent was evaporated, and the residue was purified on silica column (DCM/MeOH, 39:1→19:1→9:1→4:1) to result in 39.2 mg (82%) of the title compound as a yellow solid. 1H NMR (500 MHz, CD3OD) δ 7.44 (d, J=8.5, 2H, Ar—H), 7.29 (dd, J=1.8, 8.8, 1H, Ar—H), 7.22 (d, J=8.3, 2H, Ar—H), 7.02-6.94 (m, 2H, Ar—H), 0.18 (s, 9H, SiC3H9). 13C NMR (126 MHz, CD3OD) δ 180.56 (C—NH2), 156.85 (C—Ar), 144.59 (C—Ar), 140.89 (C—Ar), 135.13 (C—Ar), 129.58 (C—Ar), 127.89 (d, J=0.88, C—Ar), 127.66 (C—Ar), 126.99 (C—Ar), 123.70 (q, J=273.80, CF3), 117.82 (C—Ar), 116.69 (C—Ar), 107.08 (CSi(CH3)3), 92.94 (CCSi(CH3)3), 84.20 (Ar—COH), 29.55 (q, J=40.25, CN2), 0.23 (Si(CH3)3). Exact Mass, 428.13.
426.6786 [M−H]−, 428.6918 [M+H]+.
2-amino-3-{4-[3-(trifluoromethyl)diazirin-3-yl]phenyl}-5-[2-(trimethylsilyl)ethynyl]indol-3-ol (30.5 mg, 0.07 mmol, 1 eq.) was dissolved in THF (5 mL), and 1 M TBAF in THF (0.078 mL, 0.08 mmol, 1.1 eq.) was added. The reaction was stirred at room temperature for 10 minutes. Solvents were then evaporated, and the residue was purified by silica column (DCM/MeOH, 39:1→19:1→9:1→4:1), resulting in 21.8 mg (86%) of the title compound as a yellow solid. 1H NMR (500 MHz, CD3OD) δ 7.45 (d, J=8.5, 2H, Ar—H), 7.33 (dd, J=1.5, 8.0, 1H, Ar—H), 7.23 (d, J=8.2, 2H, Ar—H), 7.10-6.94 (m, 2H, Ar—H). 13C NMR (126 MHz, CD3OD) δ 180.61 (CNH2), 156.96 (C—Ar), 144.65 (C—Ar), 140.97 (C—Ar), 135.30 (C—Ar), 129.59 (C—Ar), 127.92 (d, J=0.90, C—Ar), 127.76 (C—Ar), 127.02 (C—Ar), 123.73 (q, J=273.90, CF3), 117.13 (C—Ar), 116.69 (C—Ar), 84.96 (CCH), 84.23 (Ar—COH), 77.31 (CCH), 29.56 (q, J=40.35, CN2). Exact Mass, 356.09. 354.7202 [M−H]−, 356.7268 [M+H]+.
Representative Procedures:
5-Chloro-2-aminobenzophenone (1, 15.78 g, 68.1 mmol) and formic acid (200 mL) were refluxed (117° C.) under argon for 24 h. After evaporating the excess of formic acid, the residue obtained was directly loaded onto the silica gel column (0-30% EtOAc/Hexanes) which afforded compound 2 (16.0 g, 90%) as yellow viscous oil.
A mixture of 2 (10.0 g, 38.5 mmol, 1.0 equiv) and KHCO3 (3.86 g, 38.5 mmol, 1.0 equiv) was dissolved in MeOH—H2O (1:1, 100 mL) by heating at 90° C. (oil-bath) for 15-20 min. The flask was removed from an oil bath and then KCN (3.26 g, 50.0 mmol, 1.3 equiv) was added. The reaction mixture was stirred at room temperature resulting in the precipitate formation within 1 h. The stirring was continued until LC/MS showed complete disappearance of 2 (2-3 h). Water was added to the reaction mixture and the solid was collected by filtration and washed thoroughly with water. Recrystallization with acetonitrile (preferred) or ethanol afforded compound as white solid (8.1 g, 81%).
Representative Procedures:
A microwave vial was charged with 5-chloroisatin 1 (1 g, 1.0 equiv), 1-naphthylboronic acid 2 (1.895 g, 2.0 equiv), [(C2H4)2Rh(acac)] (43 mg, 0.03 equiv, purchased from Strem), P(OPh)3 (0.11 mL, 0.07 equiv), water (0.2 mL, 2.0 equiv), and 10 mL acetone. The reaction mixture was then microwaved at 120° C. for 1 h after which the LC-MS analysis showed the completion of the reaction. 1M HCl was added to the reaction and extracted twice with CH2Cl2. The combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo to give a residue which was recrystallized from acetone/hexanes to give 3 (1.490 g, 87%) as a grey solid. Instead of doing an aqueous workup, the reaction mixture can also be directly passed through a short pad of silica gel eluting with acetone and then concentration followed by recrystallization as above.
A microwave vial was charged with 3 (300 mg, 1.0 equiv), TBDMS-NH2 4 (510 mg, 3.2 ml from the stock solution prepared below, 4.0 equiv), NMM (0.43 mL, 4.0 equiv), and 10 mL dry THF under an argon atmosphere. To this mixture was carefully added SnCl4 (1M in CH2Cl2, 2 mL, 2.0 equiv). The mixture was microwave at 110° C. for 40 min. 1M aq. HCl was added and the reaction mixture was extracted with CH2Cl2 (1×40 mL) and twice with CH2Cl2-i-PrOH mixture (while saturating the aq. phase with NaCl). The organic extracts were then combined, dried over MgSO4, filtered, concentrated in vacuo, and the residue obtained was dissolved in minimal amount of CH2Cl2 and loaded directly onto the ISCO (silica gel) column (0-7% MeOH/CH2Cl2 containing 2% Et3N) and then recrystallization with CH2Cl2/hexanes gave 5 (150 mg, yield: 50%) as an off-white solid.
Ammonia gas was bubbled (for 2-3 minutes) through a solution of TBDMSCl (5 g) in 20 mL THF at 0° C., which immediately resulted in the precipitate formation of NH4Cl. The cold bath was removed and the reaction mixture was then purged through an argon gas for 15-30 min to completely remove the unreacted ammonia. The reaction mixture was filtered through a syringe-less filter and thoroughly washed with THF in such a way that that the final volume of the solution containing TBDMS-NH2 is 24 mL. It was assumed that the yield of the reaction is 90% (3.9 g) and this solution was stored at room temperature under an argon atmosphere and used in the above reaction without further purification.
Representative Procedures:
A 20 mL capacity microwave vial was loaded with PdCl2 (0.05 equiv, 24 mg), P(1-naphthyl)3 (0.05 equiv, 56 mg), boronic acid 2 (2.0 equiv, 1.153 g), aldehyde 1 (1.0 equiv, 500 mg), K2CO3 (3.0 equiv, 1.117 g), and dry THF (12 mL). The vial was sealed and purged with N2 for 5-10 min. The reaction mixture was heated at 65° C. for 15 h, cooled to room temperature. Water was added and the reaction mixture was extracted with EtOAc (3×40 mL). The combined EtOAc extracts were dried over MgSO4, filtered, concentrated in vacuo, and the residue obtained was dissolved in minimal amount of CH2Cl2 and loaded directly onto the ISCO (silica gel) column (0-20% EtOAc/hexanes) which gave diarylmethanol 3 (500 mg, yield: 52%) as a light yellow oil.
Diarylmethanol 3 (1.0 equiv, 460 mg) was dissolved in 20 mL CH2Cl2 and to this solution was added an activated MnO2 (16.0 equiv, 1.80 g). The reaction mixture was stirred under an atmosphere of nitrogen at room temperature for 4 h after which the LC-MS analysis showed the completion of the reaction. The reaction mixture was filtered over celite and washed thoroughly with methanol and CH2Cl2. The solvents were evaporated in vacuo affording diarylketone 4 (392 mg, yield: 86%) as a light yellow oil which was used in the next step without further purification.
A mixture of 4 (390 mg, 1.0 equiv), SnCl2.2H2O (5.0 equiv, 1.244 g), few drops of conc. HCl, and 15 mL EtOH was microwaved at 130° C. for 30 min. The LC-MS analysis showed the completion of the reaction. It was found that the presence of HCl drives the reaction to completion faster than without it. (The reaction can also be performed under conventional heating, i.e. at the reflux temperature of EtOH). The solvent was evaporated in vacuo and the residue obtained was dissolved in minimal amount of CH2Cl2 and loaded directly onto the ISCO (silica gel) column (0-1% MeOH/CH2Cl2) which gave 2-aminobenzophenone 5 (321 mg, yield: 90%) as a light yellow oil.
The nitro group can also be reduced under hydrogenation conditions provided the functional groups present in the molecule are stable to the aforementioned conditions. For example:
To a solution of diarylketone 8 (600 mg) in 20 mL EtOH was added 100 mg 10% Pd/C. The reaction mixture was evacuated using house vacuum and then H2 balloon was introduced into the flask. The mixture was stirred at room temperature for 2 h (or until LC-MS showed the completion of the reaction). After completion, the reaction mixture was filtered over celite, washed with MeOH, and concentrated in vacuo to afford 9 (441 mg, 81%) as a yellow viscous oil which was used in the next step without further purification.
2-aminobenzophenone 5 (321 mg, 1.0 equiv) and formic acid (20 mL) were refluxed (117° C.) under argon for 24 h. After evaporating the excess of formic acid, the residue obtained was dissolved in minimal amount of CH2Cl2 and loaded directly onto the ISCO (silica gel) column (0-30% EtOAc/hexanes) which gave 6 (310 mg, yield: 89%) as a light yellow oil.
A mixture of 6 (310 mg, 1.0 equiv) and KHCO3 (89 mg, 1.0 equiv) was dissolved in MeOH—H2O (1:1, 6 mL) by heating at 70° C. (oil-bath) for 10-15 min. The flask was removed from an oil bath and then KCN (75 mg, 1.3 equiv) was added. The reaction mixture was stirred at room temperature overnight. The stirring was continued until LC/MS showed complete disappearance of 6. Water was added to the reaction mixture resulting in the formation of solid which was collected by filtration, washed with water and hexanes to give aminoindole 7 (220 mg, yield: 71%) as a white solid.
(Important: If addition of water does not result in the ppt. formation, then the mixture can be extracted with CH2Cl2 and once with i-PrOH—CH2Cl2 mixture (saturating the aq. phase with NaCl). The organic extracts were then combined, dried over MgSO4, filtered, concentrated in vacuo, and then recrystallization with CH2Cl2/hexanes would afford pure aminoindole).
Representative Procedures:
To a solution of N,O-dimethylhydroxylamine hydrochloride (1.5 equiv, 2.962 g) in 90% aq. EtOH (45 mL EtOH and 5 mL H2O) was added Et3N (1.5 equiv, 4.23 mL), and after 10 min of stirring at room temperature, 5-chloroisatoic anhydride 1 (1.0 equiv, 4 g) was added in portions. The reaction was then heated at reflux for 90 min and poured into an equal volume of ice and satd. aq. NaHCO3 and extracted with EtOAc (3×100 mL). The combined EtOAc extracts were dried over MgSO4, filtered, concentrated in vacuo, and the residue obtained was dissolved in minimal amount of CH2Cl2 and loaded directly onto the ISCO (silica gel) column (0-2.5% MeOH/DCM) which gave 2 (2.6 g, yield: 60%) as a light brown solid.
To a cooled (−80° C., dry ice/Et2O) mixture of 2 (0.577 g, 1.0 equiv) and bromide 3 (0.650 g, 1.0 equiv) in 30 mL dry THF under an argon atmosphere was added n-BuLi (2.5 M in hexanes, 2.2 mL, 2.05 equiv) dropwise. The mixture was stirred at the same temperature for 30 min and quenched with 1M aq. HCl and extracted with EtOAc (3×50 mL). The combined EtOAc extracts were dried over MgSO4, filtered, concentrated in vacuo, and the residue obtained was dissolved in minimal amount of CH2Cl2 and loaded directly onto the ISCO (silica gel) column (0-30% EtOAc/Hexanes) which gave 4 (0.542 g, yield: 64%) as a yellow solid.
See Example (Scheme)) for formylation and cyclization procedures.
Compound 225 was synthesized after four steps:
Step 1
A mixture of SM (1.6 g, 8 mmol), Iodoethane (1.37 g, 8.8 mmol) and K2CO3 (1.21 g, 8.8 mmol) was dissolved in DMF (10 mL) and the mixture was stirred at 70° C. under N2, overnight. The reaction mixture was diluted with H2O and extracted with EtOAc. The combined organic phase was dried over Na2SO4, filtered, concentrated in vacuo. The residue was purified by silica gel column chromatography (PE) to give a (1.5 g, 87%) as a liquid.
Step 2
To a solution of a (1.5 g, 6.88 mmol) and 2-amino-5-chloro-N-methoxy-N-methylbenzamide (1.34 g, 6.26 mmol) in anhydrous THF (40 mL) at −780 under N2 was added dropwise n-BuLi (2.5M in hexane, 7.0 mL, 17.5 mmol). The resulting solution was stirred for 1 h at the same temperature, then quenched by saturated aq. NH4Cl and extracted with ethyl acetate (3×100 mL). The organic layers were separated, combined, dried (Na2SO4) and concentrated to give a residue, which was purified by flash chromatography over silica gel (PE:EA=20:1) to yield b (1.1 g, 54%).
Step 3
A mixture of acetic anhydride (6 mL) and formic acid (3 mL) was heated at 500 with stirring for 2 h, then cooled to r.t. The resulting solution was added to a mixture of b (1.1 g, 3.75 mmol) in THF (4 mL). After the mixture was stirred at r.t. overnight, the solution was diluted with H2O. The formed solid was filtered and washed with hexane to give c (1.05 g, 87%), which was used for next step without further purification.
Step 4
A mixture of c (1.05 g, 3.27 mmol), KHCO3 (327 mg, 3.27 mmol) and KCN (638 mg, 9.81 mmol) in methanol/water (15 mL/5 mL) was stirred for 3 hrs at room temperature. After the classical work-up, the residue was purified by silica gel column chromatography (DCM/methanol) and then re-crystallized in hexane/methanol to give Compound 225 (600 mg, 57%).
The synthesis of Compound 142 was shown in synthesis scheme. a was synthesized by the reaction of 2-bromo-4-fluorophenol with ethyl iodide. Then a reacted with 2-amino-5-chloro-N-methoxy-N-methylbenzamide to give b, which was reacted with formic acid to afford c. At last, c reacted with potassium cyanide to afford Compound 142.
Step 1
To a solution of 2-bromo-4-fluorophenol (1.9 g, 10 mmol) in DMF (10 ml) was added K2CO3 (1.52 g, 11 mmol) and ethyl iodide (1.72 g, 11 mmol). The resulting mixture was stirred for 24 hrs at room temperature. The reaction mixture was diluted with H2O (40 ml) and extracted with hexane. The organic phase was washed with water, dried, filtered over a plug of silica gel and concentrated to give a (1.85 g, 85%) as a colorless oil.
Step 2
To a mixture of a (1.85 g, 8.5 mmol) and 2-amino-5-chloro-N-methoxy-N-methylbenzamide (1.82 g, 8.5 mmol) in 30 mL of dry THF under a N2 atmosphere was added dropwise n-BuLi (2.5 M in hexanes, 10.0 ml, 25 mmol) at −78° C. The resulting mixture was stirred at the same temperature for 1 h, quenched with aqueous ammonium chloride and extracted with EtOAc (3×100 mL). The combined organic phase was dried over MgSO4, filtered and concentrated in vacuo to give a residue, which was purified by silica gel column chromatography (Hexanes: EtOAc=10:1) to gave b (1.0 g, 40%) as a yellow solid.
Step 3
A solution of 2 mL of formic acid and 4 mL of acetic anhydride was heated at 50° C. for 2 h to give the acetic formic anhydride and then cooled to room temperature. To a solution of b (600 mg) in 10 mL of THF was added the acetic formic anhydride (6 mL) prepared in situ. The resulting mixture was stirred at room temperature for 3 hrs. After the completion of the reaction (TLC monitor), the solution was diluted with water (50 ml) and filtered in vacuo to give c (900 mg, 90%) as a yellow solid, which was used for next step without further purification.
Step 4
A microwave vial was charged with c (500 mg, 1.6 mmol), KCN (202 mg, 3.2 mmol) and MeOH/H2O (v/v=1/1, 10 mL). The resulting mixture was heated under microwave at 75° C. for 30 min and cooled to room temperature. The reaction solution was filtered in vacuo and the obtained solid was re-crystallized in methanol to give Compound 142 (199 mg, 40%).
Compound 201 was synthesized via a seven-step route depicted below.
Step 1
To a solution of 3-bromo-2-chloro-5-nitropyridine (23.5 g, 100 mmol) in 200 mL of CH3OH was added CH3ONa (54 g, 1.0 mol) with stirring in an ice bath. The resulting solution was heated at 80° C. for 12 hrs and cooled to room temperature. The reaction mixture was diluted with 200 mL of H2O and extracted with ethyl acetate (3×250 mL). The organic phase was dried over magnesium sulfate, filtered and concentrated to give a residue, which was purified by column chromatography over silica gel (50:1, petroleum ether/EtOAc) to afford a (6.8 g, 34%) as a yellow oil.
Step 2
To a solution of a (6.8 g, 29 mmol) in 78 mL of EtOH and 10 mL of H2O was added 0.8 mL of conc. HCl and iron powder (49 g, 174 mmol) with stirring. The resulting solution was heated at 80° C. under a nitrogen atmosphere for 3 hrs and cooled to room temperature. The reaction mixture was filtered and the filtrate was concentrated to afford b (5.1 g, 86%) as a brown-yellow residue, which was used directly to next step.
Step 3
To a solution of b (5.1 g, 25 mmol) in 22 mL of conc. H2SO4 and 28 mL of H2O was added dropwise a solution of NaNO2(1.75 g, 25 mmol) in 5 mL of H2O at 0° C. with stirring. The resulting mixture was stirred at 0° C. for 1 h, and then was added dropwise to a 34 mL of 50% aqueous H2SO4 solution under reflux. The reaction mixture was stirred under reflux for 2 hrs, cooled to room temperature, neutralized by 3N aqueous NaOH solution to pH=6 under an ice bath and extracted by EtOAc (3×150 mL). The organic phase was dried, filtered and concentrated to a residue, which was purified by column chromatography over silica gel (50:1, CH2Cl2/MeOH) to give c (1.16 g, 23%) as a white solid.
Step 4
To a solution of c (1.16 g, 5.68 mmol) and K2CO3(2.3 g, 17 mmol) in 35 mL of DMF was added one-portion CH3I (2.0 g, 14 mmol) under a nitrogen atmosphere at 0° C. with stirring. The resulting solution was heated at 50° C. for 1 h, cooled to room temperature, diluted with 100 mL of water and extracted with DCM (3×70 mL). The organic phase was dried (Na2SO4), filtered and concentrated to give a residue, which was purified by column chromatography over silica gel (50:1, petroleum ether/EtOAc) to afford d (1.1 g, 89%) as a yellow liquid.
Step 5
To a solution of d (1.1 g, 5 mmol) and 2-amino-5-chloro-N-methoxy-N-methylbenzamide (1.0 g, 5 mmol) in anhydrous THF (30 mL) was added n-BuLi (1.6 M in hexane, 9.5 mL, 15 mmol) dropwise at −78° C. under a nitrogen atmosphere with stirring. The resulting solution was stirred at −78° C. for 3 hrs, quenched by a 50 mL of saturated aqueous NH4Cl solution and extracted with DCM (3×70 mL). The organic phase was dried (Na2SO4), filtered and concentrated to give a residue, which was purified by column chromatography over silica gel (20:1, petroleum ether/EtOAc) to give e as a yellow solid (530 mg, 36%).
Step 6
To a solution of e (530 mg, 1.8 mmol) in 5 mL of THF at room temperature was added 6 mL of acetic formic anhydride solution, which was prepared by stirring a mixture of acetic anhydride (4 mL) and formic acid (2 mL) (Note that ratio of acetic anhydride volume and formic acid volume is 2:1) at 50° C. for 2 h and cooled to room temperature. The resulting solution was stirred at room temperature for 2 hrs, diluted with 50 mL of H2O and filtered to afford a yellow solid, which was washed with hexane and dried in vacuo to afford f (530 mg, 95%), which was used directly for the next step.
Step 7
To a mixture of f (530 mg, 1.65 mmol), and KHCO3 (404 mg, 4 mmol) in MeOH—H2O (v/v=1/1, 15 mL) was added KCN (263 mg, 4 mmol) one portion with stirring. The resulting solution was heated at 80° C. for 30 min, cooled to room temperature, diluted by 100 mL of water and extracted with DCM (3×70 mL). The organic phase was dried (Na2SO4), filtered and concentrated to give a residue, which was purified by column chromatography over silica gel (30:1, DCM/methanol) to afford Compound 201 (130 mg, 25%) as a white solid.
Starting materials, reagents and solvents were obtained from commercial suppliers and used without further purification. NMR spectra were obtained using a Bruker 400 instrument. 1H spectra were measured with reference to an internal standard of tetramethylsilane at 0 ppm. HPLC analysis was performed using Agilent 1100 with Zorbax 3.5μ Extend-C18 column (4.6×50 mm). Mobile phase consisting of solvent A, 0.1% trifluoroacetic acid in water, solvent B, 0.1% trifluoroacetic acid in MeCN. Gradient was from 10-90% mobile phase B in 4 minutes. Λ=210, 254 nm.
2-Amino-5-chlorobenzoic acid [635-21-2] was ordered from AK Scientific, Inc, order number: 765381.
2-Bromo-4-fluorophenol [496-69-5] was ordered from Oakwood Products, Inc, order number: 004231.
A mixture of 2-Amino-5-chlorobenzoic acid (90 g, 524 mmole) and acetic anhydride (160 ml) was heated to reflux under nitrogen for 3 hours. The reaction became a solution during heating. The reaction was cooled to room temperature. Some solid came out during this period of time. The reaction mixture was slurried with 1 L IPA and filtered. The solid was washed with more IPA (50 ml) and dried under vacuum at room temperature for 18 hours. Product was collected as solid (91 g, yield: 89%). 1H NMR (CDCl3): 8.14 (d, J=6 Hz, 1H), 7.73 (dd, J=21 Hz, 6 Hz, 1H), 7.50 (d, J=21 Hz, 1H), 2.47 (s, 3H).
2-Bromo-4-fluorophenol (105 g, 550 mmole), Ethyl iodide (110 ml, 1.37. mole) and potassium carbonate (190 g) were stirred vigorously in acetone (400 ml) at 55° C. under nitrogen for 4 hours. The reaction was cooled to room temperature and filtered. The solid was washed with more acetone (50 ml). The filtrate was concentrated on a rotary evaporator to remove most acetone (some solid came out). MTBE (600 ml) was added. The mixture was stirred for 3 minutes and filtered. The filtrate was concentrated to a clear oil (117 g, yield: 97%). 1H NMR (CDCl3): 7.28 (m, 1H), 6.96 (m, 1H), 6.83 (m, 1H), 4.05 (qt, J=18 Hz, 2H), 1.45 (t, J=18 Hz, 3H).
Making Grignard reagent: A solution of 2-ethoxy-4-fluorophenyl bromide (30 g, 138 mmol) in THF (140 ml) was added dropwisely into a stirred mixture of magnesium flake and catalytically amount of iodine under nitrogen. The result mixture was heated to reflux for 15 minutes and cooled to room temperature (Grignard reagent). In a separated flask, 6-chloro-2-methyl-4H-benzo[d][1,3]oxazin-4-one (25 g, 128 mmole) was dissolved into THF (200 ml) and stirred under nitrogen. The Grignard reagent was transferred slowly into the flask during 30 minutes. The reaction temperature was kept below 55° C. during addition. The result mixture was stirred for further 2 hours under nitrogen. The reaction was quenched by slowly addition of aqueous solution of ammonium chloride (30 g/300 ml). The reaction was extracted into MTBE (500 ml). The organic layer was washed with brine, dried (Na2SO4), filtered and concentrated on a rotary evaporator to solid. The solid was sonicated for 5 minutes in ethyl acetate (250 ml) and filtered. The filtrate was concentrated on a rotary evaporator to about 70 ml and cooled at −20° C. for 4 hours. During this time, crystallized product came out and was collected by filtration (25 g, yield: 58%). 1H NMR (CDCl3): 11.2 (br, 1H), 8.73 (d, J=22 Hz, 1H), 7.49 (dd, J=24 Hz, 7 Hz, 1H), 7.38 (d, J=6 Hz, 1H), 7.2 (m, 1H), 7.07 (dd, J=20 Hz, 8 Hz, 1H), 6.93 (m, 1H), 3.97 (q, J=17 Hz, 2H), 2.27 (s, 1H), 1.13 (tr, J=17 Hz, 3H).
N-(4-chloro-2-(2-ethoxy-5-fluorobenzoyl)phenyl)acetamide (25 g) was refluxed in a solution of concentrated HCl (6.5 ml) and ethanol (200 ml) for 3 hours. The result mixture was basified by adding aqueous sodium carbonate and extracted into MTBE (500 ml). The MTBE layer was washed by brine and dried (Na2SO4), filtered and concentrated to an oil (20 5 g, yield: 94%). 1H NMR (CDCl3): 7.20 (m, 2H), 7.11 (m, 1H), 7.00 (dd, J=20 Hz, 8 Hz, 1H), 6.91 (dd, J=23 Hz, 10 Hz, 1H), 6.65 (m, 1H), 6.34 (br, 1H), 3.39 (q, J=18 Hz, 2H), 1.19 (tr, J=18 Hz, 3H).
A mixture of (2-amino-5-chlorophenyl)(2-ethoxy-5-fluorophenyl)methanone (20.5 g, 70 mmole), zinc oxide (3 g, 37 mmole) and formic acid (28.5 ml, 740 mmole) was heated under nitrogen at 55° C. for 4 hours with vigorous stirring. The result mixture was cooled to room temperature. DCM (250 ml) was added. The reaction was filtered. The filtrate was washed by water (200 ml×2), sat. NaHCO3 (200 ml), brine (100 ml), dried (Na2SO4), filtered and concentrated to an yellow solid (20 g, yield: 89%). 1H NMR (CDCl3): 11.10 (br, 1H), 8.73 (b, J=22 Hz, 1H), 8.53 (s, 1H), 7.51 (dd, J=22 Hz, 6 Hz, 1H), 7.41 (d, J=6 Hz, 1H), 7.20 (m, 1H), 7.10 (dd, J=19 Hz, 7 Hz, 1H), 6.93 (dd, J=22 Hz, 10 Hz, 1H), 3.96 (q, J=18 Hz, 2H), 1.13 (tr, J=18 Hz, 3H). 1H NMR and HPLC of N-(4-chloro-2-(2-ethoxy-5-fluorobenzoyl)phenyl)formamide.
N-(4-chloro-2-(2-ethoxy-5-fluorobenzoyl)phenyl)formamide (20 g, 62.5 mmole) was dissolved in hot methanol (300 ml). Water (200 ml) was added (precipitated). The mixture was stirred for 2 minutes. Potassium carbonate (6.8 g, 69 mmole) was added to the stirred mixture and stirred for 2 minutes. Potassium cyanide (4.6 g, 81 mmole) was added into the stirred reaction. The mixture was stirred at room temperature for 18 hours and stirred at 70° C. (bath) for 4 hours. The reaction was cooled to room temperature and poured into water (400 ml), stirred and filtered. The solid was dried in a vacuum oven at room temperature. The solid was slurried in hot chloroform (200 ml, bath temperature: 55° C.) for 10 minutes and filtered. The solid was collected and dried (16 g, yield: 80%). 1H NMR (CDCl3): 7.72 (dd, J=24 Hz, 8 Hz, 1H), 7.13 (dd, J=20 Hz, 6 Hz, 1H), 7.00 (m, 1H), 6.91 (d, J=20 Hz, 1H), 6.80 (dd, J=22 Hz, 10 Hz, 1H), 6.76 (d, J=5 Hz, 1H), 4.85 (br, 3H), 3.78 (m, 1H), 3.58 (m, 1H), 3.31 (q, J=17 Hz, 2H), 0.97 (tr, J=17 Hz, 3H).
1H NMR and HPLC of Compound 142, 2-amino-5-chloro-3-(2-ethoxy-5-fluorophenyl)-3H-indol-3-ol
This example describes a procedure for resolving racemic Compound 142 to its enantiomers, Compounds 266 and 267, by super critical fluid chromatography (SFC). The racemic synthesis was carried out as described in Example 17 by WuXi PharmaTech. The amorphous material isolated from the SFC was crystallized to give a crystalline material that was fully characterized.
1. Separation Method:
SFC and HPLC were used for the analytical and SFC was used for preparative chiral separation.
1.1 Analytical Separation Method:
SFC-MS
Instrument: Berger Analix analytical SFC with DAD Detector
Column: ChiralPak AD-3, 150×4.6 mm ID
Mobile phase: A for SFC CO2 and B for 2-Propanol (0.05% DEA)
Gradient: B 25%
Flow rate: 2.4 ml/min
Wavelength: 220 nm
HPLC
Instrument: Shimadzu LC-20A with DAD Detector
Column: Shim-pack XR-ODS 30 mm*3 mm I.D.
Mobile phase: A for H2O (0.1% TFA) and B for Acetonitrile
Gradient: B 10-80%
Flow rate: 1.2 ml/min
Wavelength: 210 nm and 254 nm
1.2 Preparative Separation Method
Instrument: Berger MGIII preparative SFC
Column: ChiralPak AD-H, 250×30 mmI.D.
Mobile phase: A for SFC CO2 and B for 2-Propanol
Gradient: A:B 70:30
Flow rate: 80 ml/min
Sample preparation: dissolved in Ethanol, 50 mg/ml
Injection: 4 ml per injection.
After separation, the fractions were dried off via rotary evaporator at bath temperature 40° C.
2. Crystallization:
To the separated Enantiomer A and B was added Ethyl ether at amount of 50 ml/g respectively. Stir at 30° C. bath to make sure the solid was dissolved. The solution was transferred into wild-mouth bottles. Place the bottles in the ventilated hood to let Ethyl ether evaporate at controlled speed. With the solvent evaporated slowly, crystals can be seen separate out from the mother liquid. Filtrate and wash the solid with Ethyl ether for three times to give Enantiomer A and B (crystal) respectively. The mother liquid was concentrated via rotary evaporator to get Enantiomer A and B (mother liquid) respectively.
Enantiomer A and B (crystal) was grinded and dried respectively in vacuum oven at 30° C. for 24 h to remove residue Ethyl ether.
3. Quality control:
3.1e.e Test Via SFC-MS
The test was carried out under the same conditions as shown in 1.1
3.2 Purity Test Via HPLC and NMR
The test was carried out under the same conditions as shown in 1.1
3.3 Analysis of X-RPD and DSC
4. Note:
During the whole process, only Ethanol, 2-Propanol and Ethyl ether were used.
In Vitro Potency Against P. falciparum:
In vitro potency against P. falciparum was assessed using a modified version of the method of Plouffe and coworkers (Plouffe, D., A. Brinker, C. McNamara, K. Henson, N. Kato, K. Kuhen, A. Nagle, F. Adrian, J. T. Matzen, P. Anderson, T. G. Nam, N. S. Gray, A. Chatterjee, J. Janes, S. F. Yan, R. Trager, J. S. Caldwell, P. G. Schultz, Y. Zhou, and E. A. Winzeler. 2008. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA 105:9059-64). Parasites were cultured in the presence of drug in RPMI (Sigma) containing 4.16 mg/ml Albumax in a total volume of 500 at a 2.5% hematocrit and an initial parasitemia of 0.3% in black Greiner GNF clear-bottom plates. Cultures were incubated 72 hr at 37° C. under 95% N2, 4% CO2 and 3% O2. At the end of the incubation, SYBR green was added to a dilution of 1:10,000 and plates were stored overnight (or until ready to be read) at −80° C. Just before reading, plates were centrifuged at 700 rpm and fluorescence was read using 480 nm excitation and 530 nm emission frequencies. Compound concentrations that inhibit parasite replication reduce the fluorescence intensity of SYBR green bound to parasite DNA.
Results show that many aminoindoles have potent IC50 values (inhibitory concentration which reduces parasitemia by 50%) in the low double-digit nanomolar range with respect to P. falciparum strains 3D7, Dd2 and HB3 (not shown). IC50 values were determined by staining the parasites with nucleic acid stain DAPI and/or SYBR green. IC50 value ranges with respect to P. falciparum strain 3D7 for several compounds of the invention are indicated in Table 1 using asterisks (see Table 1 legend).
In Vitro Potency Against P. knowlesi:
Selected compounds were tested against P. knowlesi H1 strain parasites cultured in Rhesus blood cells as a surrogate for P. vivax infections using the method of Kocken and coworkers (Kocken, C. H., H. Ozwara, A. van der Wel, A. L. Beetsma, J. M. Mwenda, and A. W. Thomas. 2002. Plasmodium knowlesi provides a rapid in vitro and in vivo transfection system that enables double-crossover gene knockout studies. Infect Immun 70:655-660). Briefly, P. knowlesi were cultured in 2% Rhesus macaque erythrocytes (New England Primate Research Center) in RPMI culture media containing 10% Human O+ serum (Interstate Blood Bank). Schizont stage parasites were purified by floatation in 60% Percoll (GE life sciences) and allowed to reinvade to generate a synchronous population of ring stage parasites. Drug assays were performed by plating ring stage parasites at 0.5% parasitemia in triplicate, in RPMI containing 2.5 μg/ml hypoxanthine. Parasites were incubated for 24 hours with serially diluted test compounds. After 24 hours, thin smears were made to confirm that reinvasion had occurred, 0.5 μCi 3H-labeled hypoxanthine (Perkin Elmer) were added to each well, and parasites were allowed to progress through S-phase to early schizonts. Cells were then harvested via glass filter plates and 3H incorporation was measured by scintillation counting. Values were normalized to percentage of controls containing no drug, and IC50 values were generated (GraphPad Prism®). Results are shown in Table 3.
Plasmodium spp.
In Vivo Efficacy Against P. berghei in Mice:
Species of Plasmodium that infect humans (such as P. falciparum, P. vivax, P. knowlesi) do not infect or cause disease in rodents and can only be evaluated directly in primate models of infection. Because of ethical issues and costs, the acute P. berghei model in rodents is considered the “gold standard” for assessing anti-malarial efficacy in animal models. This model is adapted from Peters' “4-day suppressive test” (Peters, W. 1987. Chemotherapy and Drug Resistance in Malaria, p. 102-115, 2ed, vol. 1. Academic Press, Orlando, Fla.; Peters, W. 1975. The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity. Ann Trop Med Parasitol 69:155-171). All studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National-Research-Council. 1996. Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, D.C.) and the PHS guidelines. Animals were maintained according to NIH guidelines and were allowed to acclimatize for 1 week prior to the commencement of studies. On Day 0, groups of 4-6-week old female Swiss Albino mice (n=5) were infected by tail vein injection with 0.2 ml heparinized blood diluted to contain 1×107 N-clone parasites. The aminoindole analogs were formulated in 1.6% lactic acid mixed sodium salt, 1% Tween 80, 9% ethanol and 20% Cerestar (hydroxypropyl β-cyclodextrin; Wacker Chimie) and were administered by oral gavage. On Day 0, a single dose was given at 6 hr post initial infection, and over the subsequent 3 days the dose was split and administered b.i.d., with 6 hours between doses. Animals in the Control-group received vehicle alone. Dose concentration and frequency of dosing were based upon preliminary tolerability/exposure studies. On Day 4 post-infection (5th day of assay) blood was collected by tail-nick, and thin smear microscope slides were prepared and stained using Diff Quick®. Parasitized erythrocytes were counted and compared with the total number of erythrocytes per microscopic field to determine the percent parasitemia. A minimum of 350 erythrocytes were counted. Animals showing no detectable parasites on Day 4 were examined every 2-3 days to determine whether cure was sterile. Animals with no detectable parasites 28 days after cessation of dosing (Study Day 33) were considered cured.
Results (Table 4) show that selected aminoindoles are highly active against P. berghei, suppressing parasitemia on Study Day 5 by 81-100%. Compound 3, Compound 37, Compound 142 and Compound 267 all were able to affect cures at doses of 100-200 mg/kg/day.
0/5)
In Vivo Efficacy Against P. falciparum in Mice:
Because rodent malaria species (such as P. berghei) are not necessarily identical to human species (such as P. falciparum) with respect to sensitivity to antimalarial compounds, a “humanized mouse” model has been developed that supports the erythrocytic cycle of P. falciparum. Compound 267 was tested for efficacy against P. falciparum Pf3D0087/N9 growing in NOD-scid IL-2Rγnull mice engrafted with human erythrocytes (Angulo-Barturen, I., et al. 2008. PLoS ONE 3:e2252). Briefly, groups of 3 animals were infected on Day 0 with 2×107 P. falciparum parasites and were treated orally once per day for 4 days with 5, 25 and 100 mg/kg/day formulated as described above beginning on Day 3 post infection. In parallel, groups of 3 animals were infected on Day 0 with 1×107 parasites on Day 0 and received the same doses beginning 1 hr after infection. Parasitemia was assessed by FACS as previously described (Jiménez-Díaz, M.-B., et al. 2009. Cytometry Part A 75:225-235. In the same humanized murine system, efficacy was also tested against P. berghei, with animals infected on Day 0 (Jimenez-Diaz, M. B., et al. 2005. Cytometry A 67:27-36). Results are shown in Table 5.
P. berghei
P. berghei
P. falciparum
The teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety.
While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
This application is the U.S. National Stage of International Application No. PCT/US2010/054473, filed Oct. 28, 2010, which designates the U.S., published in English, and claims the benefit of U.S. Provisional Application No. 61/256,879, filed Oct. 30, 2009. The entire teachings of the above applications are incorporated herein by reference.
This invention was made with government support under Grant Nos. CA078048 and NS053660 and NS50767 awarded by the National Institutes of Health. The Government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US2010/054473 | 10/28/2010 | WO | 00 | 4/27/2012 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2011/053697 | 5/5/2011 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3576001 | Bell et al. | Apr 1971 | A |
| 3577435 | Bell et al. | May 1971 | A |
| 3586693 | Bell et al. | Jun 1971 | A |
| 3686210 | Bell et al. | Aug 1972 | A |
| 3714188 | Bell et al. | Jan 1973 | A |
| 3801593 | Bell et al. | Apr 1974 | A |
| 3931226 | White et al. | Jan 1976 | A |
| 6605634 | Zablocki et al. | Aug 2003 | B2 |
| 8431538 | Kozikowski et al. | Apr 2013 | B2 |
| 20050101654 | Welberth et al. | May 2005 | A1 |
| Number | Date | Country |
|---|---|---|
| 2 921 061 | Mar 2009 | FR |
| 55-79366 | Jun 1980 | JP |
| 55-133346 | Oct 1980 | JP |
| 57-002271 | Jan 1982 | JP |
| 58-015990 | Jan 1983 | JP |
| Entry |
|---|
| Witulski, et al., “Palladium-Catalyzed Synthesis of 2-Aminoindoles by a Heteroannulation Reaction,” Angewandte Chemie International Edition, 42(35): 4257-4260 (2003). Abstract only. |
| Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or The Declaration for PCT/US2010/054473, titled “2-Aminoindole Compounds and Methods for the Treatment of Malaria”; Date of Mailing: Jan. 27, 2011 (10 pgs.). |
| International Preliminary Report on Patentability from counterpart International Application No. PCT/US2010/054473, “2-Aminoindole Compounds and Methods for the Treatment of Malaria”, Dated: May 10, 2012. |
| Supplementary Search Report and Opinion in European International Application No. 10827467.1, Title: “2-Aminoindole Compounds and Methods for the Treatment of Malaria”, dated: Mar. 26, 2013. |
| Database Caplus [Online] Chemcial Abstracts Service, Columbus, OH; Asahi Chemical Industry: “2-aminoindolenine derivatives”, XP002693790, retrieved from STN, Database accession No. 1982:455687; & JP 57 002271 A (Asahi Chemical Industry Co., Ltd., Japan) (Jan. 7, 1982). |
| Ishizumi, K., et al., Quinazolines. II: Oxidation of 2-Aminoindoles and Related Compounds:, Journal of Organic Chemistry, vol. 39(17):2581-2587 (1974). |
| Benincori, T. and Sannicolo, F., “New Access to 2-(Arylazo)-, 2-(Arythydrazo)-, and 2-Aminoindoles, -benzofurans, and -thianaphtenes”, Journal of Organic Chemistry, vol. 53(6):1309-1312 (1988). |
| Urgaonkar, S., et al., “A Concise Silylamine Approach to 2-Amino-3-hydroxy-indoles with Potent in vivo Antimalaria Activity”, Organic Letters, vol. 12(18):3998-4001 (2010). |
| Plouffe, D., et al., “In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen,” Proc., Natl. Acad. Sci. USA, 105:9059-64 (2008). |
| Kocken, C.H., et al., “Plasmodium knowlesi Provides a Rapid In Vitro and In Vivo Transfection System That Enables Double-Crossover Gene Knockout Studies” Infect. Immun., 70(2):655-660 (2002). |
| Sakiyama, F., et al., “Chemical Interconversion of Tryptophan and N′-Formylkynurenine,” Chemistry Letters, pp. 1109-1112 (1979). |
| Sakiyama, F., et al., “Conversion of 3-Alkylindole to 3-Alkyl-2-Amino-3H-Indo1-3-Ol via Alkyl 2-Formamidophenyl Ketone,” Chemistry Letters, pp. 587-590 (1979). |
| Waterhouse, I., et al., “Synthesis of Carbon-14 Labelled Indolic 5HT1Receptor Agonists,” J. of Labelled Components and Radiopharmaceuticlas, XXXVIII(11):1021-1030 (1996). |
| Belley, M., et al., “Synthesis and Reactivity of N-Hydroxy-2-Amino-3-Arylindoles,” Synlett, 19:2991-2994 (2007). |
| Baniecki, M.L., et al., “High-Throughput Plasmodium falciparum Growth Assay for Malaria Drug Discovery,” Antimicrobial Agents and Chemotherapy, 51(2):716-723 (2007). |
| Nakazawa, T., et al., “Chemical Conversion of kynurenine to tryptophan”, Peptide Chemistry, vol. 16, pp. 11-16 (1979). |
| Golubeva, G.A., et al., “Indole chemistry. XXXV. Synthesis of 2-amino-3-alkylindoles”, Chemistry of Heterocyclic Compounds, Issue 4, pp. 511-516 (1973). |
| Bell, S., et al., “Ring closure reactions with nitriles. III. Formation of 2-amino- and 2-oxo-3-hydroxyindoles from the reaction of 2′-aroylacylanilides with cyanide”, Journal of Heterocyclic Chemistry, 6(5):599-604 (1969). |
| Wittig, G., et al, “o-Benzidine rearrangement of 3-methyl-4-phenylhydrazo-5-phenylisoxazole”, Justus Liebigs Annalen der chemie, vol. 469, pp. 1-16 (1929). |
| Number | Date | Country | |
|---|---|---|---|
| 20120232063 A1 | Sep 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61256879 | Oct 2009 | US |
